Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C269
- Development stage
- Preclinical
- Lead developer
- University of Pavia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
C269 is a candidate monoclonal antibody that targets extracellular Nicotinamide phosphoribosyltransferase (eNAMPT). eNAMPT is a cytokine that is elevated in patients with Inflammatory Bowel Disease (IBD) and is associated with resistance to anti-TNF therapies. C269 binds to eNAMPT and neutralizes its cytokine activity, thereby reducing inflammation, immune cell infiltration, and fibrosis. In preclinical models of IBD (DSS and DNBS), C269 has demonstrated efficacy in reducing symptoms. It is being investigated as a potential therapeutic strategy for IBD patients, particularly those who are non-responsive to standard biologic treatments.
- Other names
- anti-eNAMPT antibody
02
Targets
NAMPT
Beyond the preview
Go deeper on C269.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C269.